Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

Benzer Materyaller

• Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
  Yazar:: Kurozumi, Sasagu, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
  Yazar:: Kurozumi, Sasagu, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer
  Yazar:: Kurozumi, Sasagu, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology
  Yazar:: Sven Kurbel, ve diğerleri
  Baskı/Yayın Bilgisi: (2017-03-01)
• Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
  Yazar:: Burcombe, R J, ve diğerleri
  Baskı/Yayın Bilgisi: (2005)